Clearstone exiting cardiac services to focus on core labs

By Nick Taylor

- Last updated on GMT

Related tags Clearstone central laboratories Laboratory Clearstone

Clearstone Central Laboratories is to wind down or sell its centralised cardiac services (CCS) business because significant investment would be required to remain competitive.

Since acquiring assets from MDS Pharma Services, Clearstone has taken a number of steps to restructure and refocus the organisation. The latest of these is the decision to exit the CCS business.

CCS is a relatively small part of the business, Bernie Clark, director, global marketing and communications, told Outsourcing-Pharma. Consequently, it was felt too great an investment would have been needed to remain competitive against specialist companies in the market.

The move will impact sites in Toronto, Canada and Paris, France but it is unclear at this stage how many employees will be affected and over what timeframe.

Clearstone will continue to support clients currently using CCS but has stopped accepting new business. As the current business finishes the company will lay off employees to align staffing with demand.

In a press statement Lewis Cameron, CEO of Clearstone, said: “We will be taking every step possible to support affected staff and continue providing clients with the highest level of service during the transition period​.”

The transition period will either end with CCS closing or being sold. Clark said it would be premature to predict the outcome but believes finding a buyer would be good news for everyone.

Core lab focus

Exiting the CCS sector will allow Clearstone to focus resources on its core laboratory business. This contributes the majority of revenues and since acquiring it from MDS Clearstone has talked about expanding its geographic reach and service offering.

Clark said that this is continuing through investments in pharmacogenomics, the Apollo central laboratory protocol management system and operations in Beijing, China. In earlier interviews Clearstone has expressed an interest in expanding into Latin America, India and Russia.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us


View more